Content Type: Commentary & Opinion

Letter to the Editor Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”

March 6, 2026

Drug Repurposing Via the Best Pharmaceuticals for Children Act

March 6, 2026

The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease

March 6, 2026

State Spending Targets for Prescription Drugs

March 6, 2026

Op-Ed: This Gene Therapy May Not Work. So Why Did the FDA Fully Approve It?

March 6, 2026

Misaligned Pharmacy Incentives in Value-Based Care

March 6, 2026

Revisiting the Potential of “Money Blinds”: Lessons From Lykos’s MDMA Research

March 6, 2026

Merging Medical and Drug Benefits: Seeing the Whole Picture

March 6, 2026

The Origins of “Confidential Commercial Information” at the FDA

March 6, 2026

The FDA in the Crosshairs-Science, Politics, and Abortion

March 6, 2026

From “Price Controls” to Robust Public Conversation: How CMS Can Move Drug Price Negotiation Into the Light

March 6, 2026

The Value of the Quality-Adjusted Life Years

March 6, 2026